BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakamura T, Kawakami K, Nomura M, Sato Y, Hyodo M, Hatakeyama H, Hayakawa Y, Harashima H. Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.03.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Zhu H, Lin L, Zhao W, Zhu X, Pang DW, Liu AA. Redox Imbalance Triggered Intratumoral Cascade Reaction for Tumor "turn on" Imaging and Synergistic Therapy. Small 2023;:e2206272. [PMID: 36683231 DOI: 10.1002/smll.202206272] [Reference Citation Analysis]
2 Chen S, Peng A, Chen M, Zhan M. Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1093240] [Reference Citation Analysis]
3 Fekrirad Z, Barzegar Behrooz A, Ghaemi S, Khosrojerdi A, Zarepour A, Zarrabi A, Arefian E, Ghavami S. Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy. Cancers 2022;14:3698. [DOI: 10.3390/cancers14153698] [Reference Citation Analysis]
4 Khalifa AM, Nakamura T, Sato Y, Sato T, Hyodo M, Hayakawa Y, Harashima H. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. Int J Pharm 2022;624:122034. [PMID: 35863595 DOI: 10.1016/j.ijpharm.2022.122034] [Reference Citation Analysis]